Trial · NCT07890753
Biological Aging Following Full-Arch Implant-Supported Fixed Rehabilitation in Edentulous Patients
NCT07890753, Not yet recruiting, Junyu Shi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biological Aging Following Full-Arch Implant-Supported Fixed Rehabilitation in Edentulous Patients. Trials, record NCT07890753. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890753
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biological Aging Following Full-Arch Implant-Supported Fixed Rehabilitation in Edentulous Patients
- NCT number
- NCT07890753
- Status
- Not yet recruiting
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Junyu Shi
- Conditions
- Edentulism, Biological Aging
- Interventions
- Full-Arch Implant-Supported Fixed Dental Rehabilitation
- First posted
- 2026-10-22
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Salivary DNA Methylation Age Acceleration | Baseline, 3 months, 12 months, and 24 months | Biological age acceleration will be assessed as the difference between DNA methylation-derived biological age estimated from saliva samples and chronological age, expressed in years. Changes from baseline will be evaluated longitudinally and compared between the implant rehabilitation cohort and the delayed-treatment comparison cohort. |
| Secondary | Change in Facial Biological Age Acceleration | Baseline, 3 months, 12 months, and 24 months | Facial biological age will be estimated from standardized facial photographs using an artificial intelligence-based age estimation method. The difference between estimated facial biological age and chronological age, expressed in years, will be assessed longitudinally. |
| Secondary | Change in Handgrip Strength | Baseline, 3 months, 12 months, and 24 months | Handgrip strength will be measured using a standardized grip strength assessment. Longitudinal changes in handgrip strength will be evaluated. |
| Secondary | Change in Gait Speed | Baseline, 3 months, 12 months, and 24 months | Gait speed will be assessed using a standardized walking assessment to evaluate longitudinal changes in physical performance. |
| Secondary | Change in Physical Frailty | Baseline, 3 months, 12 months, and 24 months | Physical frailty will be assessed using the Fried Frailty Phenotype, which evaluates five components: unintentional weight loss, self-reported exhaustion, low physical activity, slow walking speed, and weak grip strength. Each component is scored as 0 (criterion absent) or 1 (criterion present), yielding a total score ranging from 0 to 5. Higher scores indicate greater frailty. Scores of 0 indicate robustness, scores of 1-2 indicate prefrailty, and scores of 3-5 indicate frailty. Changes in total frailty scores and frailty categories will be evaluated longitudinally. |
| Secondary | Change in Oral Health-Related Quality of Life | Baseline, 3 months, 12 months, and 24 months | Oral health-related quality of life will be assessed using the 14-item Oral Health Impact Profile (OHIP-14). Each item is scored from 0 (never) to 4 (very often), yielding a total score ranging from 0 to 56. Higher scores indicate greater negative impacts of oral health on quality of life and therefore worse oral health-related quality of life. Changes in total OHIP-14 scores from baseline will be evaluated longitudinally. |
| Secondary | Change in Nutritional Status | Baseline, 3 months, 12 months, and 24 months | Nutritional status will be assessed using the Mini Nutritional Assessment-Short Form (MNA-SF), which has a total score ranging from 0 to 14. Higher scores indicate better nutritional status. Scores of 0-7 indicate malnutrition, 8-11 indicate risk of malnutrition, and 12-14 indicate normal nutritional status. Changes in total scores from baseline will be evaluated longitudinally. |
| Secondary | Change in Anxiety Symptoms Assessed by the Beck Anxiety Inventory (BAI) | Baseline, 3 months, 12 months, and 24 months | Anxiety symptoms will be assessed using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63. Higher scores indicate greater severity of anxiety symptoms. Changes in total BAI scores from baseline will be evaluated longitudinally. |
| Secondary | Change in Depressive Symptoms Assessed by the Beck Depression Inventory (BDI) | Baseline, 3 months, 12 months, and 24 months | Depressive symptoms will be assessed using the Beck Depression Inventory (BDI), a 21-item self-report questionnaire. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63. Higher scores indicate greater severity of depressive symptoms. Changes in total BDI scores from baseline will be evaluated longitudinally. |
| Secondary | Change in Global Cognitive Function | Baseline, 3 months, 12 months, and 24 months | Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), with total scores ranging from 0 to 30. Higher scores indicate better global cognitive performance. Changes in total MoCA scores from baseline will be evaluated longitudinally. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Symbol Coding | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890753
GET https://conductscience.org/api/trials/v1/NCT07890753/registered